Ann: Neurizon Files IND Application to Support HEALEY ALS Trial, page-49

Hi All,
I found this on X. As Michael alluded to during the mid year update, we should not be concerned that others are turning their attention towards ALS. Particularly when, like in this case big pharma companies like Bristol Myers Squibb turn their attention to ALS. This particular case involves a very early stage treatment, and attracted a modest $US 50 million up front. But has potential to receive 2 billion plus royalties.

Having multiple competitors chasing the same target particularly when they are less advanced than NUZ001, can be a very good thing, as larger companies jostle for a position on the start line. Business 101.

I see the board now has 2 separate but equally important tasks.

1. Steer NUZ001 through the P2/3 trial and convince the FDA/EMA/TGA that NUZ001 should receive accelerated approval.
2. Build a business case to create tension and competitiveness between potential partners/acquirers so they feel they need to get involved.

Now that the IND has been submitted, various team members can now concentrate on their specific roles. E.g

• The COO John Clarke can oversee the relationship with Healey, [The default trial manger] and all day to day activities.
• The CSO Nicki Wallis can concentrate on the Lab Work.
• The Production Manager Herb Brinkman can oversee the tablet production and distribution.
• The CEO Michael Thurn and the Business Development Officer Paul Field can work with BP to see what they want and sell NUZ as something they should be involved with.

All the above would have been deeply involved in preparing the IND application [Perhaps with the exception of Paul] and it would have taken a lot of time and effort.

In my view the evolution of NUZ has entered a new stage. I'm confidant will get a return, just how much we will have to wait and see. I recall the words of Dr Katie MacFarlane, possibly our most experienced board member who is both a scientist and an entrepreneur. " They will be begging to come on board"

https://www.businesswire.com/news/home/20241218771566/en/insitro-Receives-25-Million-in-Milestone-Payments-from-Bristol-Myers-Squibb-for-the-Achievement-of-Discovery-Milestones-and-the-Selection-of-First-Novel-Genetic-Target-for-ALS



Cheers